Status: Recruiting
Safety of RSV Preventive Monoclonal Antibody
This is a prospective, randomized, open-label clinical trial to evaluate the safety of administration of respiratory syncytial virus (RSV) preventive monoclonal antibody and other routine childhood vaccines given simultaneously at Visit 1, as compared to sequential administration of respiratory syncytial virus (RSV) preventive monoclonal antibody and other vaccines at separate visits (Visits 1 and 2).
Participants needed: 524
Trial details
Phase: Phase 4Age: 6-30Biological sex: AllType: InterventionalSponsor: Duke UniversityUpdated: Mar 16, 2026Locations: 6
Eligibility criteria
Infants ≥ 6 weeks to <30 weeks of age at the time of enrollment [+6]
Known contraindication or precaution to RSV monoclonal antibody or other routine... [+17]